Evolent Health (EVH) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Business overview and clinical model

• Focuses on improving adherence to evidence-based treatment in complex diseases like oncology and cardiology, aiming to raise adherence from 65% to 85% and reduce costs through fewer treatment errors and hospitalizations.

• Engages directly with physicians to support optimal care decisions, leveraging a team of 300 clinicians and a mix of fee and risk-based contracts.

• Emphasizes holistic patient management, integrating radiology and specialty care for better outcomes.

Recent acquisitions and integration

• Completed integration of NIA, with 90% of tech integration finished and successful cross-selling of oncology products to existing NIA customers.

• Acquired Machinify, an AI-driven platform, to enhance internal clinical efficiency and offer SaaS solutions to external payers.

• Machinify is expected to reduce clinical review time by up to 50% and generate $50 million in long-term impact through staff efficiencies.

Financial performance and growth outlook

• Achieved improved profitability and positive stock reaction following the second quarter, attributed to differentiated clinical value.

• Maintains a $300 million run-rate EBITDA target by year-end, with plans to sustain 20% EBITDA growth thereafter.

• Organic growth rate is around 35%, with a focus on balancing top-line expansion and profitability.